指南与共识骨质疏松与钙磷/甲状旁腺

绝经后女性骨质疏松症的药物管理:内分泌学会指南更新

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update.
指南 / 共识 · J Clin Endocrinol Metab · 2020-01-01

本指南更新基于Meta分析和原发性临床试验,评估硬骨抑素单克隆抗体罗莫索单抗预防骨折的疗效,结论认为该药可考虑作为骨折极高风险绝经后女性的治疗选择。罗莫索单抗说明书含黑框警告,因活性对照试验显示其与阿仑膦酸钠之间严重心血管不良事件存在不平衡,建议临床医生仔细评估个体心血管风险。

要点

  • 罗莫索单抗可考虑用于骨折极高风险的绝经后女性。
  • 说明书黑框警告要求评估个体心血管风险。
  • 试验显示罗莫索单抗与阿仑膦酸钠严重心血管事件不平衡。

核心结论

  • 罗莫索单抗可考虑作为骨折极高风险绝经后女性的治疗选择。

研究设计与样本

  • 制定机构为内分泌学会,方法为对2019年指南进行更新,基于Meta分析和原发性临床试验,评估罗莫索单抗预防骨折的疗效。

主要发现

  • 活性对照试验数据显示罗莫索单抗与阿仑膦酸钠之间严重心血管不良事件存在不平衡。

关键数值与推荐

  • 罗莫索单抗说明书含黑框警告,建议治疗医生仔细考虑可能接受该药个体女性的心血管风险特征。

临床怎么用

  • 罗莫索单抗可考虑用于骨折极高风险的绝经后女性。
  • 处方罗莫索单抗时需按黑框警告仔细评估个体心血管风险特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective is to provide an update of the 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline for the pharmacological management of osteoporosis in postmenopausal women using romosozumab. CONCLUSIONS: We reviewed findings from the meta-analysis and primary clinical trials assessing the efficacy of romosozumab, a monoclonal antibody targeting sclerostin, for the prevention of fractures and concluded that this agent can be considered a treatment option for postmenopausal women at very high risk for osteoporotic fracture. The romosozumab label has a boxed warning, recommending careful consideration by the treating clinician as to cardiovascular risk profile in the individual woman who might receive this agent, since clinical trial data from an active comparator study show an imbalance in serious cardiovascular adverse events between romosozumab and alendronate.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shoback D, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020. PMID: 32068863. doi:10.1210/clinem/dgaa048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。